Click Here for 5% Off Your First Aladdin Purchase!

carotegrast , CAS No.401904-75-4, Inhibitor of integrin α4β1;Inhibitor of integrin α4β7;Inhibitor of integrin; alpha 4 subunit (antigen CD49D; alpha 4 subunit of VLA-4 receptor)

  • Moligand™
  • ≥98%
Item Number
C608326
Grouped product items
SKUSizeAvailabilityPrice Qty
C608326-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$59.90
C608326-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,334.90
C608326-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$299.90
C608326-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,001.90
C608326-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$999.90
C608326-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,529.90

Basic Description

SynonymsCarotegrast|401904-75-4|Carotegrast [INN]|UNII-Y1HYC6SO3F|Y1HYC6SO3F|(2S)-2-(2,6-dichlorobenzamido)-3-(4-(6-(dimethylamino)-1-methyl-2,4-dioxo-1,4-dihydroquinazolin-3(2h)-yl)phenyl)propanoic acid|CHEMBL4592659|(2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[6-(
Specifications & Purity≥98%
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of integrin α4β1;Inhibitor of integrin α4β7;Inhibitor of integrin; alpha 4 subunit (antigen CD49D; alpha 4 subunit of VLA-4 receptor)
Product Description

Carotegrast is an α4 integrin receptor inhibitor with anti-inflammatories activities.发送消息记录备注 安排活动 2 正在关注中 0

Associated Targets

ITGA4 Tclin Integrin alpha-4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ITGB7 Tclin Integrin beta-7 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ITGB1 Tclin Integrin beta-1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[6-(dimethylamino)-1-methyl-2,4-dioxoquinazolin-3-yl]phenyl]propanoic acid
INCHI InChI=1S/C27H24Cl2N4O5/c1-31(2)17-11-12-22-18(14-17)25(35)33(27(38)32(22)3)16-9-7-15(8-10-16)13-21(26(36)37)30-24(34)23-19(28)5-4-6-20(23)29/h4-12,14,21H,13H2,1-3H3,(H,30,34)(H,36,37)/t21-/m0/s1
InChi Key YQKBOUPIOWUMTE-NRFANRHFSA-N
Canonical SMILES CN1C2=C(C=C(C=C2)N(C)C)C(=O)N(C1=O)C3=CC=C(C=C3)CC(C(=O)O)NC(=O)C4=C(C=CC=C4Cl)Cl
Isomeric SMILES CN1C2=C(C=C(C=C2)N(C)C)C(=O)N(C1=O)C3=CC=C(C=C3)C[C@@H](C(=O)O)NC(=O)C4=C(C=CC=C4Cl)Cl
Alternate CAS 401904-75-4
PubChem CID 10120218
Molecular Weight 555.41

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Sugiura T, Kageyama S, Andou A, Miyazawa T, Ejima C, Nakayama A, Dohi T, Eda H.  (2013)  Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice..  J Crohns Colitis,  (11): (e533-42).  [PMID:23623333]
2. Vetter M, Neurath MF.  (2017)  Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges..  Therap Adv Gastroenterol,  10  (10): (773-790).  [PMID:29051788]
3. White JR, Phillips F, Monaghan T, Fateen W, Samuel S, Ghosh S, Moran GW.  (2018)  Review article: novel oral-targeted therapies in inflammatory bowel disease..  Aliment Pharmacol Ther,  47  (12): (1610-1622).  [PMID:29672874]
4. Fukase H, Kajioka T, Oikawa I, Ikeda N, Furuie H.  (2020)  AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects..  Br J Clin Pharmacol,  86  (3): (591-600).  [PMID:31658381]
5. Shukla T, Sands BE.  (2019)  Novel Non-biologic Targets for Inflammatory Bowel Disease..  Curr Gastroenterol Rep,  21  (5): (22).  [PMID:31016396]

Solution Calculators